MedTrace Logo

DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma

NCT06933836 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2025-04-18

No results posted yet for this study

Summary

DSLT demonstrates a ≥ 20% reduction of IOP from pre-treatment baseline in POAG patients naïve of previous glaucoma treatment at 12 months.

Conditions

  • Open Angle Glaucoma (OAG)

Interventions

DEVICE

DSLT enables newly diagnosed patients to remain well controlled and off medications

DSLT enables newly diagnosed patients to remain well controlled and off medications

Sponsors & Collaborators

  • Alcon, a Novartis Company

    collaborator INDUSTRY

  • Barnet Dulaney Perkins Eye Centers

    lead NETWORK

Principal Investigators

  • Christine Funke, Medical Doctor · Barnet Dulaney Perkins Eye Centers

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2027-11-30
Completion
2027-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06933836 on ClinicalTrials.gov